N
TCRR

Nuveen’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Nuveen’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-169,674
Closed -$467K – 3579
2022
Q1 		$467K Buy
169,674
+59,286
+54% +$186K ﹤0.01% 3035
2021
Q4 		$511K Sell
110,388
-10,419
-9% -$65.1K ﹤0.01% 3069
2021
Q3 		$1.21M Buy
120,807
+4,043
+3% +$57.1K ﹤0.01% 2919
2021
Q2 		$1.92M Sell
116,764
-1,478
-1% -$29.9K ﹤0.01% 2736
2021
Q1 		$2.61M Sell
118,242
-19,590
-14% -$534K ﹤0.01% 2493
2020
Q4 		$4.26M Buy
137,832
+25,605
+23% +$647K ﹤0.01% 2155
2020
Q3 		$2.28M Buy
112,227
+31,843
+40% +$559K ﹤0.01% 2311
2020
Q2 		$1.24M Buy
80,384
+43,210
+116% +$498K ﹤0.01% 2532
2020
Q1 		$288K Buy
37,174
+123
+0.3% +$1.5K ﹤0.01% 2937
2019
Q4 		$530K Buy
37,051
+7,021
+23% +$109K ﹤0.01% 2894
2019
Q3 		$451K Buy
+30,030
New +$468K ﹤0.01% 2975

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Nuveen's TCRR Position: Q2 2022 in Review

Nuveen sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 169,674 shares — an estimated $467K sold.

Nuveen first reported a position in TCRR in Q3 2019 and held it in 11 quarters. The position peaked at $4.26M in Q4 2020. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Nuveen reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 169,674 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $467K.
  • Nuveen first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • Nuveen's TCR2 Therapeutics Inc. Common Stock position peaked at $4.26M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.